Enzim daripada cacing L.Rubellus - Lumbrokinase

Lumbrokinase is an enzyme derived from earthworms Lumbricus rubellus. Research has shown that lumbrokinase may support healthy coagulation of blood within normal levels and enhance fibrinolytic activity, i.e. similar to nattokinase.

Lumbrokinase (LK) consists of a group of proteolytic enzymes including plasminogen activator and plasmin extracted from a specific species of earthworm. The plasminogen activator (e-PA) in LK is similar to tissue plasminogen activator (t-PA) from other sources, which makes it possible to show the thrombolytic activity only in the presence of fibrin. Therefore, LK has the advantage of not causing excessive bleeding. The activity of LK is much higher than most traditional Chinese products that are available in the United States. Four phases of clinical studies have been done on LK at the Beijing Xuanwu Hospital (the top hospital in nerve & internal medicine in China). LK has been widely used in over 100 hospitals in Beijing since 1995. In Jakarta, LK has been used in thousands of hospitals and stores, in more than 20 provinces and cities, as well as in Hong Kong, Taiwan, Southeast Asia, and Europe.

LK is recognized by the Ministry of Public Health in China. LK capsules technology was awarded a certificate of National Significance Achievement in Science and Technology, listed as the Promotional project of National Key Technology Achievement and the National Torch Plan Program, and selected as National Key New product by six major ministries.

MECHANISM OF ACTION:

Evidence shows lumbrokinase supports the inhibition of the intrinsic coagulation pathway and the activation of fi brinolysis via an increase of t-PA activity. Lumbrokinase activates plasminogen and hydrolyzes fi brin directly, reduces ESR, C-RP, TXB2, and lowers blood viscosity and platelet aggregation function. FDP and D-Dimer levels have been shown to increase sharply within three days of Lumbrokinase administration. The rate at which Lumbrokinase lowers plasma fi brinogen levels varies depending on the condition being treated. Research results range from a 21% reduction in 12 weeks to a 33% reduction in 21days. On average a reduction rate of 10 to 20% or more in 4 weeks can be expected when patients are on the full dosage of 2 capsules three times daily. Lumbrokinase will not reduce plasma fi brinogen levels to below normal.

PUBLISHED RESEARCH STUDIES:
In a Chinese study conducted at Beijing Tongren Hospital1,patients with hyperfi brinogenemia were orally administered sixtablets of lumbrokinase per day for three weeks. Serum fi brinogenlevels were examined before and after treatment. In comparison with the control groups given antilipemia or antiplatelet aggregation drugs, serum fi brinogen in the lumbrokinase treated group signifi cantly decreased two weeks after treatment in a time related manner [before treatment (5.34 ± 0.48) g/L, two weeks after treatment (4.33 ± 1.09) g/L, three weeks after treatment (3.71 ± 0.48) g/L]. These results showed lumbrokinase could relieve hyperfi brinogenemia, and that the formation of thrombi would be decreased. Lumbrokinase had few reported side effects.Additional research investigated the effect of lumbrokinase on antiocoagulation and fi brinolysis in treating cerebral infarction2. Patients were randomly divided into the lumbrokinase treatment group (n=31) or a control group (n=20). The single blind method was used in this investigation and the Chinese stroke score was used to evaluate the results of treatment before and after administration of lumbrokinase. Kaolin partial thromboplastin time (KPTT), prothrombin time (PT), fi brinogen content, and vWF content were analyzed, while tissue plasminogen activator (t-PA) activity, plasminogen activator inhibitor (PAI) activity, D-dimer level were assayed.

In both groups the stroke score decreased after administration, but in the treatment group, it was more obvious. In the treatment group KPTT was prolonged, t-PA activity and D-dimer level increased, while the content of fi brionogen decreased signifi cantly. There were no signifi cant changes of PT and PAI activity in both groups. The researchers concluded that lumbrokinase is benefi cial to the treatment of cerebral infarction and the effect of lumbrokinase is related to the inhibition of intrinsic coagulation pathway and the activation of fi brinolysis via an increase of t-PA activity.